MilliporeSigma Capabilities Update June 2026: ADC

Two experienced CDMOs are aligning their strengths to streamline the path from development to commercialization for antibody-drug conjugates (ADCs). By combining deep technical expertise with coordinated, cross-site support, they are building a more connected approach to complex manufacturing programs. Close collaboration enables smoother tech transfers, stronger communication across teams, and greater consistency in outcomes. Real-world examples highlight how integrated project management, analytical development, and testing can reduce friction and keep timelines on track. For teams navigating the challenges of ADC development, these insights offer a clearer view of how strategic partnerships can improve efficiency and accelerate progress.

Discover how a unified model can help bring advanced therapies to patients with greater speed and confidence.